

Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study

Duo LV^{1,2}, Xishao XIE^{3,4,5,6,7}, Qinyun YANG⁸, Zhimin CHEN^{3,4,5,6,7}, Guangjun LIU^{3,4,5,6,7}, Wenhan PENG^{3,4,5,6,7}, Rending WANG^{3,4,5,6,7}, Hongfeng HUANG^{3,4,5,6,7}, Jianghua CHEN^{3,4,5,6,7}, Jianyong WU^{3,4,5,6,7}

¹Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

²Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China

³Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

⁴Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou 310003, China

⁵Institute of Nephrology, Zhejiang University, Hangzhou 310003, China

⁶Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou 310003, China

⁷The Third Grade Laboratory under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310003, China

⁸Information Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

Table S1 Univariate analysis of risk factors for mortality in hospitalized kidney transplant recipients with COVID-19

Characteristics	Unadjusted HR (95% CI)	P value
Age (years)	1.04 (1.01–1.07)	0.007
Age>59 years	2.54 (1.30–4.97)	0.006
Gender (male)	1.19 (0.65–2.19)	0.571
BMI (kg/m ²)	0.98 (0.9–1.07)	0.653
<1 year since transplant to COVID-19 symptom onset (yes)	1.69 (0.89–3.21)	0.110
Deceased donor (yes)	0.28 (0.10–0.78)	0.015
Previous transplantation (yes)	3.16 (0.98–10.22)	0.055
Hypertension (yes)	2.08 (0.88–4.94)	0.096
Diabetes (yes)	1.88 (1.02–3.49)	0.044
Cardiovascular disease (yes)	1.86 (1.02–3.42)	0.044
Cerebrovascular disease (yes)	3.88 (1.38–10.88)	0.01
Peripheral vascular disease (yes)	2.68 (1.35–5.33)	0.005
Respiratory disease (yes)	1.73 (0.85–3.52)	0.129
Malignancy (yes)	1.54 (0.48–4.99)	0.470
CMV infection (yes)	2.30 (0.56–9.52)	0.251
EBV infection (yes)	2.03 (1.06–3.91)	0.033
Creatinine level on admission (per 1 mg/dL)	1.17 (1.06–1.29)	0.002
Hb (per 10 g/L)	0.79 (0.69–0.90)	0.001
Hb<90 g/L	2.83 (1.42–5.63)	0.003
Serum albumin (g/L)	0.86 (0.80–0.92)	< 0.001
Serum albumin <33 g/L	3.92 (2.10–7.31)	< 0.001
Neutrophile (×10 ⁹ L ⁻¹)	1.08 (1.03–1.14)	0.002
Lymphocyte (10 ⁹ L ⁻¹)	0.11 (0.03–0.4)	0.001

Neutrophile/lymphocyte ratio	1.02 (1.02–1.03)	< 0.001
Neutrophile/lymphocyte ratio>30	6.79 (3.68–12.54)	< 0.001
C-reactive protein (mg/L)	1.04 (0.99–1.09)	0.162
IL-6 level (per 10 pg/mL)	1.01 (1.00–1.01)	< 0.001
IL-6>6.8 pg/mL	5.84 (2.58–13.23)	< 0.001
Severe COVID-19 (yes)	1.98 (1.04–3.75)	0.038
Antimetabolite withdraw	1.31 (0.32–5.45)	0.709
CNI withdraw	2.24 (0.30–16.90)	0.434
Antiviral therapy (yes)	7.77 (2.40–25.16)	0.001
Baricitinib use (yes)	1.42 (0.68–2.97)	0.349
Tocilizumab use (yes)	5.24 (2.84–9.67)	< 0.001
Immunoglobulin use (yes)	5.72 (3.10–10.56)	< 0.001
AKI (yes)	9.06(4.64–17.72)	< 0.001
Fungal infection (yes)	8.94 (4.82–16.58)	< 0.001
Corticosteroids (per day per 10 mg)	1.05 (1.02–1.09)	0.002
Corticosteroids>50 mg/d (yes)	1.01 (1.00–1.02)	0.062

BMI, body mass index; Hb, hemoglobin; CMV, cytomegalovirus; EBV, Epstein-Barr virus; CNI, calcineurin inhibitors, AKI, acute kidney injury; HR, hazard ratio; CI, confidence interval.